IP Library Granted Patent US 9,663,561
Granted Patent B2
US 9,663,561 · App. 14/607,426 · Granted May 30, 2017

Methods of treatment of cancer using SRC-modulating peptides

Inventors: Zi-Jian Xie (Saline, MI); Joseph I. Shapiro (Toledo, OH); Jiang Tian (Perrysburg, OH); Zhichuan Li (Williamsville, NY)
Assignee: The University Of Toledo
C07K14/4702A61K38/10A61K38/1709A61K38/45A61K38/46C07K7/08C07K14/4703C07K14/4705C12Y207/10002C12Y306/03009G01N33/573
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,561
App. No.
14/607,426
Granted
May 30, 2017
Kind
B2
Abstract

A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction between the Na/K-ATPase and Src, act via a different mechanism from ATP analogues, and is pathway (Na+/K+-ATPase) specific. Also disclosed is use of said Src-modulating peptides for treatment of cancer.

Claims (5)

1. A method for inhibiting prostate cancer cell growth in a subject in need thereof, the method comprising:

administering an effective amount of an isolated peptide comprising the amino acid sequence of the Src-modulating peptide (P3) having SEQ ID NO:2, sufficient to inhibit prostate cancer cell growth.

2. The method of claim 1 , wherein the isolated peptide is linked to a cell-penetrating peptide selected from the group consisting of: penatratin (TAT) having SEQ ID NO: 47, and atennapedia (AP) having SEQ ID NO: 48.

3. A method for inhibiting prostate cancer cell growth in a subject in need thereof, the method comprising:

administering an effective amount of an isolated peptide comprising the amino acid sequence having SEQ ID NO:49, sufficient to inhibit prostate cancer cell growth.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jun 13, 2017
From: UNIVERSITY OF TOLEDO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042776/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2015
From: XIE, ZI-JIAN; SHAPIRO, JOSEPH I.; TIAN, JIANG
To: THE UNIVERSITY OF TOLEDO
Reel/Frame 034840/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2015
From: LI, ZHICHUAN
To: THE UNIVERSITY OF TOLEDO
Reel/Frame 034840/0343 →
Continuity (4)
Division 13625162 · Sep 24, 2012
Division 12446856
Provisional Application 60855482 · Oct 31, 2006
Related Publication 20150133389A1 · May 14, 2015